The financials
Elanco Animal Health Incorporated by the numbers
Elanco Animal Health Incorporated (ELAN) reported revenue of $1.37B in Q2 2026 (quarter ended June 30, 2026), up 10% from the same quarter a year earlier. That came with a gross margin of 58% and net income of $54M (3.9% of revenue). For the full year FY2025, revenue was $4.71B (+6.2% year on year) and net income −$232M. Its largest product in 2026-Q1 was Pet Health at $710M, 52% of the disclosed total, just ahead of Cattle at 23%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $1.37B | $1.24B | +10% |
| Gross profit | $798M | $713M | +12% |
| Net income | $54M | $11M | +391% |
| Diluted EPS | $0.11 | $0.02 | +450% |
| Product | Revenue | Share |
|---|---|---|
| Pet Health | $710M | 52% |
| Cattle | $316M | 23% |
| Poultry | $230M | 17% |
| Swine | $96M | 7.0% |
| Contract Manufacturing | $19M | 1.4% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $1.37B (+21%)
Contract Manufacturing grew +58% year on yearPet Health +12% year on year
Segment Latestquarter on quarteryear on year
- Pet Health$710.0M$710.0MQoQ +33%year on year +12%+33%+12%
- Cattle$316.0M$316.0MQoQ +9.3%year on year +16%+9.3%+16%
- Poultry$230.0M$230.0MQoQ +6.0%year on year +22%+6.0%+22%
- Swine$96.0M$96.0MQoQ +10%year on year +13%+10%+13%
- Contract Manufacturing$19.0M$19.0MQoQ +73%year on year +58%+73%+58%
- Aqua--QoQ -year on year ---
Drug Manufacturers - Specialty & Generic
Ranks #1 of 28 by Smart Score